• 제목/요약/키워드: microtubule-binding molecules

검색결과 6건 처리시간 0.025초

DRG2 Deficiency Causes Impaired Microtubule Dynamics in HeLa Cells

  • Dang, Thao;Jang, Soo Hwa;Back, Sung Hoon;Park, Jeong Woo;Han, In-Seob
    • Molecules and Cells
    • /
    • 제41권12호
    • /
    • pp.1045-1051
    • /
    • 2018
  • The developmentally regulated GTP binding protein 2 (DRG2) is involved in the control of cell growth and differentiation. Here, we demonstrate that DRG2 regulates microtubule dynamics in HeLa cells. Analysis of live imaging of the plus-ends of microtubules with EB1-EGFP showed that DRG2 deficiency (shDRG2) significantly reduced the growth rate of HeLa cells. Depletion of DRG2 increased 'slow and long-lived' subpopulations, but decreased 'fast and short-lived' subpopulations of microtubules. Microtubule polymerization inhibitor exhibited a reduced response in shDRG2 cells. Using immunoprecipitation, we show that DRG2 interacts with tau, which regulates microtubule polymerization. Collectively, these data demonstrate that DRG2 may aid in affecting microtubule dynamics in HeLa cells.

Effects of Tubulyzines, Novel Microtubule-Binding Triazine Molecules, on Endothelial Progenitor Cell Differentiation

  • Park, Hyo-Eun;Lee, Soo-Young;Ahn, Hyun-Young;Shin, Jong-Cheol;Chang, Young-Tae;Joe, Young-Ae
    • Biomolecules & Therapeutics
    • /
    • 제11권2호
    • /
    • pp.85-90
    • /
    • 2003
  • Microtubule-binding molecules have been developed as anti-cancer agents to overcome the toxicities of current chemotherapeutics and also have potential for use as anti-angiogenic agents. In this work, we examined the effect of novel triazine compounds, Tubulyzines (microTUBUle LYsing triaZINE), derived from the orthogonal synthesis of a triazine library, on endothelial progenitor cell differentiation. When mononuclear cells isolated from human cord blood were cultured on fibronectin-coated plates for 7 days, all the Tubulyzine compounds A, B, and C (TA, TB, and TC) tested decreased the number of adherent cells in a dose-dependent manner in a coo. centration ranges of 2-5 to $80\mu\textrm{M}$. TA ($IC_{50}$=$20\mu\textrm{M}$) showed slightly more potent activity than TB and TC. Adherent cells treated with TA also exhibited a lower level of ability to ac-LDL uptake, with low ratios of positive cells out of total adherent cells, in a dose-dependent manner and weak expression of endothelial lineage markers, KDR, CD31, and vWF at $20\mu\textrm{M}$. Therefore, these results suggest that tubulyzine A (TA) can be effectively used for the inhibition of new vessel growth by inhibiting differentiation of endothelial progenitor cells.

Pharmacophore Models of Paclitaxel- and Epothilone-Based Microtubule Stabilizing Agents

  • Lee, Sangbae;Lee, Yuno;Briggs, James M.;Lee, Keun Woo
    • Bulletin of the Korean Chemical Society
    • /
    • 제34권7호
    • /
    • pp.1972-1984
    • /
    • 2013
  • Microtubules play an important role in intracellular transport, mobility, and particularly mitosis. Paclitaxel (Taxol$^{TM}$) and paclitaxel-like compounds have been shown to be anti-tumor agents useful for various human tumors. Paclitaxel-like compounds operate by stabilizing microtubules through interface binding at the interface between two ${\beta}$-tubulin monomers in adjacent protofilaments. In this paper we present the elucidation of the structural features of paclitaxel and paclitaxel-like compounds (e.g., epothilones) with microtubule stabilizing activities, and relate their activities to spatial and chemical features of the molecules. CATALYST program was used to generate three-dimensional quantitative structure activity relationships (3D-QSARs) resulting in 3D pharmacophore models of epothilone- and paclitaxel-derivatives. Pharmacophore models were generated from diverse conformers of these compounds resulting in a high correlation between experimental and predicted biological activities (r = 0.83 and 0.91 for epothilone and paclitaxel derivatives, respectively). On the basis of biological activities of the training sets, five- and four-feature pharmacophore hypotheses were generated in the epothilone and paclitaxel series. The validation of generated hypotheses was achieved by using twelve epothilones and ten paclitaxels, respectively, which are not in the training sets. The clustering (grouping) and merging techniques were used in order to supplement spatial restrictions of each of hypothesis and to develop more comprehensive models. This approach may be of use in developing novel inhibitor candidates as well as contributing a better understanding of structural characters of many compounds useful as anticancer agents targeting microtubules.

Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs

  • Kim, Youngmi;Kim, Hyuna;Jeoung, Dooil
    • Molecules and Cells
    • /
    • 제38권8호
    • /
    • pp.705-714
    • /
    • 2015
  • We investigated the role of HDAC3 in anti-cancer drug-resistance. The expression of HDAC3 was decreased in cancer cell lines resistant to anti-cancer drugs such as celastrol and taxol. HDAC3 conferred sensitivity to these anti-cancer drugs. HDAC3 activity was necessary for conferring sensitivity to these anti-cancer drugs. The down-regulation of HDAC3 increased the expression of MDR1 and conferred resistance to anti-cancer drugs. The expression of tubulin ${\beta}3$ was increased in drug-resistant cancer cell lines. ChIP assays showed the binding of HDAC3 to the promoter sequences of tubulin ${\beta}3$ and HDAC6. HDAC6 showed an interaction with tubulin ${\beta}3$. HDAC3 had a negative regulatory role in the expression of tubulin ${\beta}3$ and HDAC6. The down-regulation of HDAC6 decreased the expression of MDR1 and tubulin ${\beta}3$, but did not affect HDAC3 expression. The down-regulation of HDAC6 conferred sensitivity to taxol. The down-regulation of tubulin ${\beta}3$ did not affect the expression of HDAC6 or MDR1. The down-regulation of tubulin ${\beta}3$ conferred sensitivity to anti-cancer drugs. Our results showed that tubulin ${\beta}3$ serves as a downstream target of HDAC3 and mediates resistance to microtubule-targeting drugs. Thus, the HDAC3-HDAC6-Tubulin ${\beta}$ axis can be employed for the development of anti-cancer drugs.

Kinesin Light Chain (KLC)의 Tetratricopeptide Repeat (TPR) 도메인을 통한 Scaffold 단백질 WAVE1과 Kinesin 1의 결합 (The Scaffolding Protein WAVE1 Associates with Kinesin 1 through the Tetratricopeptide Repeat (TPR) Domain of the Kinesin Light Chain (KLC))

  • 장원희;정영주;엄상화;석대현
    • 생명과학회지
    • /
    • 제26권8호
    • /
    • pp.963-969
    • /
    • 2016
  • Kinesin superfamily proteins (KIFs)은 세포 내 소기관이나 단백질복합체를 미세소관을 따라 운반하는 모터단백질이다. Kinesin 1은 경쇄단위체(light chain subunit)를 통하여 결합함으로써 세포 내 소기관, 신경소포, 신경전달물질수용체, 신호전달단백질, mRNA 등 다양한 운반체를 운반하는 KIFs의 한 종류이다. Kinesin light chains (KLCs)은 모터기능이 없는 단위체로서 kinesin heavy chains (KHCs) 이량체와 결합하여 kinesin 1을 구성한다. KLCs은 여러 단백질과 결합하지만 아직 결합단백질이 충분히 밝혀지지 않았다. 본 연구에서 KLC1의 tetratricopeptide repeat (TPR) 영역과 결합하는 단백질을 분리하기 위하여 효모 two-hybrid 탐색을 수행한 결과 Wiskott-Aldrich syndrome의 원인단백질이며 액틴 세포골격 조절단백질인 WASP/WAVE family의 하나인 WAVE1을 분리하였다. WAVE1은 KLC1의 TPR 영역을 포함한 부위와 결합하지만 KHCs인 KIF5A, KIF5B, KIF5C와는 결합하지 않았다. 또한 KLC1은 WAVE1의 C-말단에 존재하는 verprolin/cofilin/acidic (VCA) 도메인과 결합하였으며, 다른 WAVE isoform인 WAVE2와 WAVE3과도 결합하였다. HEK-293T 세포에 WAVE1과 KLC1을 동시에 발현시켰을 때 두 단백질이 세포 내에서 같은 부위에 존재하며, WAVE1을 면역침강한 결과 KLC1뿐만 아니라 KIF5B가 같이 침강함을 확인하였다. 이러한 결과들은 kinesin 1이 WAVE 단백질복합체 혹은 WAVE로 덮여있는 운반체를 운반함을 시사한다.

Kinesin Light Chain 1 (KLC1)의 Tetratricopeptide Repeat (TPR) 도메인과 Rab effector, EHBP1L1의 결합 (Rab Effector EHBP1L1 Associates with the Tetratricopeptide Repeat Domain of Kinesin Light Chain 1)

  • 정영주;박성우;김상진;김무성;엄상화;이정구;석대현
    • 생명과학회지
    • /
    • 제30권1호
    • /
    • pp.10-17
    • /
    • 2020
  • Kinesin 1은 미세소관을 따라 plus말단으로 이동하는 모터단백질로 세포내 물질 수송에 관여한다. Kinesin 1은 경쇄단위체(light chain subunit)를 통하여 운반체들인, 세포내 소기관, 다양한 소포체, 신경전달물질 수용체 단백질, 세포신호전달 단백질과 여러 단백질 복합체들과 결합하여 운반하는 kinesin superfamily protein (KIFs)의 한 종류이다. Kinesin light chains 1 (KLC1)은 모터 기능이 없는 단위체로서 kinesin heavy chain (KHC)과 결합한다. KLC1은 다양한 매개단백질들과 결합하지만 아직 결합하는 매개단백질이 충분히 밝혀지지 않았다. 본 연구에서는 KLC1의 tetratricopeptide repeat (TPR) 영역과 결합하는 단백질을 분리하기 위하여 효모 two-hybrid 탐색한 결과 EH domain-binding protein 1-like 1 (EHBP1L1) 을 분리하였다. EHBP1L1은 KLC1의 TPR 영역을 포함한 부위와 결합하지만 KIF5B (kinesin 1의 모터 단백질)과 KIF3A (kinesin 2의 모터 단백질)와는 결합하지 않았다. 또한 KLC1은 EHBP1L1의 C-말단에 존재하는 coiled-coil 도메인과 결합하였으며, 다른 EHBP1L1의 isoform인 EHBP1과는 결합하지 않았다. KLC1은 GST와는 결합하지 않지만 GST-EHBP1L1과 GST-EHBP1L1-coiled-coil domain과는 결합하였다. HEK-293T세포에 EHBP1L1과 KLC1을 동시에 발현시켰을 때 두 단백질은 세포 내에서 같은 부위에 존재하며, EHBP1L1을 면역침강한 결과 KLC1뿐만 아니라 KIF5B와도 같이 침강함을 확인하였다. 이러한 결과들은 kinesin 1은 EHBP1L1이 결합한 운반체를 수송함을 시사한다.